Dr. Fraser joined Abide in March of 2014 and is the Vice President of Early Clinical Development. He brought with him more than eight years of experience in the early phases of clinical drug development (clinical pharmacology and experimental medicine). Prior to joining Abide, Dr. Fraser spent 7 years at Merck Research Laboratories where he was responsible for entry to the clinic of a number of development candidates across a diverse range of therapeutic areas including diabetes, inflammation, and infectious diseases. In addition, he oversaw the conduct of clinical pharmacology studies to support submission packages for later-stage development candidates. This included designing and supervising Phase 1 studies in pediatric patient populations in support of pediatric-specific regulatory submissions.

 Dr. Fraser joined Abide in March of 2014 and is the Vice President of Early Clinical Development. He brought with him more than eight years of experience in the early phases of clinical drug development (clinical pharmacology and experimental medicine). Prior to joining Abide, Dr. Fraser spent 7 years at Merck Research Laboratories where he was responsible for entry to the clinic of a number of development candidates across a diverse range of therapeutic areas including diabetes, inflammation, and infectious diseases. In addition, he oversaw the conduct of clinical pharmacology studies to support submission packages for later-stage development candidates. This included designing and supervising Phase 1 studies in pediatric patient populations in support of pediatric-specific regulatory submissions.